Compare SLE & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | KROS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 206.0M |
| IPO Year | 2019 | 2020 |
| Metric | SLE | KROS |
|---|---|---|
| Price | $5.00 | $11.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $60.00 | $21.86 |
| AVG Volume (30 Days) | ★ 328.0K | 159.9K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ N/A |
| Revenue | $2,064,000.00 | ★ $243,864,000.00 |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $49.77 | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.48 | $9.69 |
| 52 Week High | $11.43 | $22.55 |
| Indicator | SLE | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 52.28 |
| Support Level | $2.66 | $10.57 |
| Resistance Level | $5.24 | $11.61 |
| Average True Range (ATR) | 0.44 | 0.41 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 80.26 | 42.86 |
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.